This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana (HUM) Issues $1.25B Senior Notes, To Lower Debt Level
by Zacks Equity Research
Humana (HUM) issues senior notes with the intent to procure funds to trim its escalating debt level.
Encompass Health (EHC) Proposes 50-Bed Hospital in Florida
by Zacks Equity Research
Encompass Health (EHC) intends to build a 50-bed inpatient rehabilitation hospital in the Daytona Beach area to further amplify its presence in Florida.
Zacks.com featured highlights include Conagra Brands, Medpace Holdings, BP, Avis Budget Group and Liberty Energy
by Zacks Equity Research
Conagra Brands, Medpace Holdings, BP, Avis Budget Group and Liberty Energy are part of Zacks Screen of the Week article.
Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
5 Stocks With Upgraded Broker Ratings to Fight Macro Challenges
by Swayta Shah
As brokers have more insight into stocks, one must follow rating upgrades before investing. We pick Conagra Brands (CAG), Medpace Holdings (MEDP), BP, Avis Budget Group (CAR) & Liberty Energy (LBRT), as these have seen rating upgrades.
Are Medical Stocks Lagging Immunocore (IMCR) This Year?
by Zacks Equity Research
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Medpace (MEDP) have performed compared to their sector so far this year.
Did Midterm Voters Help Stocks Out?
by John Blank
They usually do. Markets don't like political uncertainty.
Humana's (HUM) Arm to Aid Senior Care, 2023 Expansion on Track
by Zacks Equity Research
Humana's (HUM) CenterWell brand plans to open centers in untapped markets as well as dig deeper into the existing regions offering enhanced primary care services to the nation's senior citizens.
National Vision (EYE) Q3 Earnings Top Mark, Margins Down
by Zacks Equity Research
National Vision (EYE) is facing demand headwinds across its network of stores due to the constraints on eye exam capacity.
Globus Medical (GMED) Q3 Earnings Miss Estimates, EPS View Cut
by Zacks Equity Research
Internationally, Globus Medical (GMED) reports double-digit growth in most markets, with the U.K., Australia, Brazil, India and Poland registering more than 40% growth.
Cardiovascular Systems (CSII) Q1 Earnings Miss, Revenues Top
by Zacks Equity Research
The launch of the Scoreflex scoring balloon receives a positive response and generates over $1.7 million in sales during the first quarter for Cardiovascular Systems (CSII).
Haemonetics (HAE) Q2 Earnings Beat Estimates, 2023 View Up
by Zacks Equity Research
Under the Hospital segment, despite continued macroeconomic, Haemonetics (HAE) meaningfully grows revenues and market share.
BD (BDX) Q4 Earnings and Revenues Beat Estimates, Margins Up
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal fourth quarter.
QIAGEN's (QGEN) Q3 Earnings Top Estimates, 2022 View Up
by Zacks Equity Research
The ongoing double-digit sales growth in the non-COVID product portfolio, a high level of profitability and strong cash flow are the major upsides for QIAGEN (QGEN).
STERIS (STE) Q2 Earnings Miss Estimates, Margins Increase
by Zacks Equity Research
Barring AST, poor reported revenue performance across three of STERIS' (STE) operating segments poses concerns.
Surmodics (SRDX) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust Medical Device revenues.
Masimo (MASI) Q3 Earnings Top Estimates, 2022 View Revised
by Zacks Equity Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q3 sales.
Insulet (PODD) Q3 Earnings Beat Estimates, '22 Sales View Up
by Zacks Equity Research
Insulet's (PODD) performance benefits from record quarterly U.S. and Total Omnipod new customer starts.
Syneos Health (SYNH) Q3 Earnings Miss Estimates, '22 View Cut
by Zacks Equity Research
Syneos Health (SYNH) Q3 revenues are below the guidance primarily due to the impact of lower net new business awards, delays in backlog conversion and customer delays in its FSP business.
OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) third-quarter results reflect dismal segmental performances.
PerkinElmer (PKI) Q3 Earnings Top, Revenues Decline Y/Y
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, which was more than offset by lower COVID-related sales.
Shockwave Medical (SWAV) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.
PacBio's (PACB) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
PacBio (PACB) witnesses strength in Service and other revenues, along with robust consumable sales, in the third quarter.
Bruker (BRKR) Q3 Earnings Beat Estimates, '22 Sales View Down
by Zacks Equity Research
Despite ongoing macroeconomic headwinds, Bruker (BRKR) registers strong demand for differentiated high-value scientific instruments and life science solutions.
Omnicell (OMCL) Q3 Earnings Beat Estimates, Guidance Cut
by Zacks Equity Research
Rise in operating expenses result in an operating loss in Q3 for Omnicell (OMCL), placing significant pressure on the bottom line.